S-531011

Cat. No.: HY-P991481 Purity: 98.38%: Data Sheet
COA

SDS

FAQs
Technical Support

S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8⁺regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma.

For research use only. We do not sell to patients.

S-531011 Chemical Structure

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of S-531011:

S-531011 (FUT8-KO) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CCR Isoform Specific Products:

View All Isoforms

CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 CCR9

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[1]

CCR8

18.6 pM (Kd)

In Vitro

S-531011 binds to CCR8 with an in vitro-measured association rate constant of 11.9 L/nmol/hr and a calculated dissociation rate constant of 6.65 1/hr^[2].
S-531011 (0.08-0.3 nmol/L; overnight) binds specifically and with high affinity to human CCR8 (K_d = 18.6 pmol/L) and its CCR8^A27G variant (K_d = 26.4 pmol/L) expressed on HEK293T cells, with no cross-reactivity to other tested receptors^[3].
S-531011 (up to 300 μg/mL; 2 hours) lacks CDC activity against Ramos-hCCR8 cells, with no measurable EC₅₀ at concentrations up to 300 μg/mL^[3].
S-531011 (0.001-10 μg/mL; overnight) selectively depletes tumor-infiltrating Tregs, but not Tconv cells, in human NSCLC and ovarian cancer tissues via ADCC, whereas Mogamulizumab (HY-P99253) depletes both populations^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

S-531011 (0.15-15 mg/kg; i.v.; 2 doses (days 4 and 11 post tumor inoculation)) induces potent dose-dependent antitumor activity in CT26.WT tumor-bearing hCCR8 KI mice, with significant tumor volume reduction observed at doses of 0.15, 5, and 15 mg/kg^[3].
S-531011 (100 μg/mouse; i.v.; 2 doses (days 5 and 12 post tumor inoculation)) induces potent antitumor activity in EMT6 tumor-bearing hCCR8 KI mice, with significantly greater tumor volume reduction than vehicle or anti-mouse PD-1 antibody treatment^[3].
S-531011 (10 mg/kg; i.v.; single dose (day 5 post tumor inoculation)) enhances the antitumor activity of anti-mouse PD-1 antibody in CT26.WT tumor-bearing hCCR8 KI mice without observable adverse effects^[3].
S-531011 (0.05-5 mg/kg; i.v.; single dose (day 8 post tumor inoculation)) induces dose-dependent depletion of tumor-infiltrating CCR8⁺ Tregs in CT26.WT tumor-bearing hCCR8 KI mice, with effects lasting at least 7 days after a single dose^[3].
S-531011 (0.05-0.5 mg/kg; i.v.; single dose (day 8 post tumor inoculation)) induces dose-dependent depletion of tumor-infiltrating CCR8⁺ Tregs in Colon26 tumor-bearing hCCR8 KI mice 4 days after a single dose^[3].
S-531011 (0.05-0.5 mg/kg; i.v.; single dose (day 8 post tumor inoculation)) induces dose-dependent depletion of tumor-infiltrating CCR8⁺ Tregs in EMT6 tumor-bearing hCCR8 KI mice 4 days after a single dose^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	humanized CCR8 knock-in (hCCR8 KI) (female, CT26.WT colorectal cancer cells subcutaneously implanted)^[3]
Dosage:	0.15 mg/kg; 0.5 mg/kg; 1.5 mg/kg; 5 mg/kg; 15 mg/kg
Administration:	i.v.; 2 doses (days 4 and 11 post tumor inoculation)
Result:	Reduced tumor volumes significantly in the 0.15, 5, and 15 mg/kg groups compared with isotype control antibody group (P < 0.05, P < 0.001, P < 0.001, respectively, on day 19 after inoculation).

Animal Model:	humanized CCR8 knock-in (hCCR8 KI) (female, EMT6 mammary carcinoma cells subcutaneously implanted)^[3]
Dosage:	100 μg/mouse
Administration:	i.v.; 2 doses (days 5 and 12 post tumor inoculation)
Result:	Reduced tumor volumes significantly compared with vehicle control group (P < 0.0001) and anti-mouse PD-1 antibody-treated group (P < 0.05) on day 28 after implantation.

Animal Model:	humanized CCR8 knock-in (hCCR8 KI) (female, CT26.WT colorectal cancer cells subcutaneously implanted)^[3]
Dosage:	10 mg/kg
Administration:	i.v.; single dose (day 5 post tumor inoculation)
Result:	Suppressed tumor volume significantly when combined with anti-mouse PD-1 antibody compared with S-531011 alone (P < 0.05) on day 21 after inoculation. Caused no reduction in body weight or worsening of general condition.

Animal Model:	humanized CCR8 knock-in (hCCR8 KI) (female, CT26.WT colorectal cancer cells subcutaneously implanted)^[3]
Dosage:	0.05 mg/kg; 0.5 mg/kg; 5 mg/kg
Administration:	i.v.; single dose (day 8 post tumor inoculation)
Result:	Reduced the proportion of CCR8⁺ Tregs relative to total Tregs in a dose-dependent manner at 4 and 7 days post-administration (P < 0.001 and P < 0.0001 for all doses vs. isotype control).

Animal Model:	humanized CCR8 knock-in (hCCR8 KI) (female, Colon26 colorectal cancer cells subcutaneously implanted)^[3]
Dosage:	0.05 mg/kg; 0.5 mg/kg
Administration:	i.v.; single dose (day 8 post tumor inoculation)
Result:	Reduced the proportion of CCR8⁺ Tregs relative to total Tregs in a dose-dependent manner (P < 0.05 for 0.05 mg/kg, P < 0.01 for 0.5 mg/kg vs. saline) 4 days after administration.

Animal Model:	humanized CCR8 knock-in (hCCR8 KI) (female, EMT6 mammary carcinoma cells subcutaneously implanted)^[3]
Dosage:	0.05 mg/kg; 0.5 mg/kg
Administration:	i.v.; single dose (day 8 post tumor inoculation)
Result:	Reduced the proportion of CCR8⁺ Tregs relative to total Tregs in a dose-dependent manner (P < 0.05 for 0.05 mg/kg, P < 0.01 for 0.5 mg/kg vs. saline) 4 days after administration.

Clinical Trial

Gene ID

1237 [NCBI]

Accession

P51685

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

148.11 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[S-531011]

Shipping

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 98.38%

Select Batch:

Data Sheet (267 KB) SDS (251 KB)

COA (232 KB) SDS-PAGE (180 KB) SEC-HPLC (204 KB)

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Kobayashi H, et al. Epitope mapping of an anti-mouse CCR8 monoclonal antibody C8Mab-2 using flow cytometry[J]. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 2024, 43(4): 101-107.

[2]. Yamaguchi D, et al. Modeling for prediction of CCR8 receptor occupancy in human tumor tissues after dosing of S-531011, a humanized anti-CCR8 monoclonal antibody[C]//American Conference of Pharmacometrics. International Society of Pharmacometrics, 2026: S-036.

[3]. Nagira Y, et al. S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. Mol Cancer Ther. 2023;22(9):1063-1072. [Content Brief]

S-531011 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

S-531011S531011S 531011CCRCC chemokine receptorperipheral blood-derived regulatory T cellsanti-PD-1 antibodytumor-infiltrating CCR8+ regulatory T cellshuman-CCR8 knock-in mouse modelsadvanced solid tumorshuman CCR8non-small cell lung cancercolon cancerHEK293T cellsovarian cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *